论文部分内容阅读
目的:探讨周剂量奈达铂化疗联合调强放疗对于复发鼻咽癌患者的近期疗效及安全性。方法:将2009年2月至2012年2月本院收治的56例鼻咽癌复发患者随机分为联合治疗组与单纯放疗组,两组患者均给予适形调强放疗,联合治疗组患者在此基础上给予周剂量奈达铂化疗治疗,比较两组患者的临床疗效、并发症的发生情况及近期生存情况。结果:联合治疗组和单纯放疗组的有效率分别为78.6%和50.0%,联合治疗组有效率显著高于单纯放疗组(P<0.05);联合治疗组白细胞减少发生率显著高于单纯放疗组(P<0.05),其他并发症的发生率比较无显著差异(P>0.05);联合治疗组1年、2年生存率分别为85.7%、64.3%,显著高于单纯放疗组的60.7%、42.9%(P<0.05)。结论:联合周剂量奈达铂化疗能够显著提高复发鼻咽癌患者调强放疗的临床疗效,且未增加严重并发症风险,值得临床推广应用。
Objective: To investigate the short-term efficacy and safety of weekly dose of Nedaplatin combined with intensity modulated radiotherapy for patients with recurrent nasopharyngeal carcinoma. Methods: Fifty-six patients with nasopharyngeal carcinoma recurred in our hospital from February 2009 to February 2012 were randomly divided into combined therapy group and radiotherapy alone group, and both groups received conformal IMRT. In the combined therapy group, On the basis of weekly dose of nedaplatin chemotherapy, compared the clinical efficacy of two groups of patients, the incidence of complications and recent survival. Results: The effective rates of combination therapy group and radiotherapy alone group were 78.6% and 50.0%, respectively, and the effective rate of combination therapy group was significantly higher than that of radiotherapy alone group (P <0.05). The incidence of leukopenia in combination therapy group was significantly higher than that of radiotherapy alone group (P <0.05). There was no significant difference in other complication rates between the two groups (P> 0.05). The 1-year and 2-year survival rates were 85.7% and 64.3% in the combined treatment group, significantly higher than 60.7% 42.9% (P <0.05). Conclusion: Combined weekly nedaplatin chemotherapy can significantly improve the clinical efficacy of IMRT in patients with recurrent nasopharyngeal carcinoma, and does not increase the risk of serious complications, which deserves clinical application.